This section of the IDEAYA Biosciences InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. IDEAYA Biosciences assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQIDYA
| Beta | 2.09 |
|---|---|
| Shares Outstanding | 29.1M |
| Average Volume (10 days) | 428.6K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Strong Buy |
|---|
| Strong Buy | 8 | |
|---|---|---|
| Buy | 0 | |
| Hold | 0 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Jason Throne SVP, General Counsel | (400) Sell Dec 4, 2020 |
|---|---|
Jason Throne SVP, General Counsel | (1,579) Sell Dec 4, 2020 |
Paul Stone SVP, Chief Financial Officer | (2,500) Sell Jun 17, 2020 |
Paul Stone SVP, Chief Financial Officer | (600) Sell Jun 17, 2020 |
Mark Lackner SVP, Head of Biology | (373) Sell Jun 17, 2020 |
